Catalyst Pharmaceuticals' (CPRX) Buy Rating Reaffirmed at HC Wainwright

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $30.00 target price on the biopharmaceutical company's stock. HC Wainwright's price target indicates a potential upside of 25.37% from the stock's current price.

Other equities analysts have also recently issued research reports about the company. Citigroup boosted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, August 9th. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Truist Financial boosted their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $29.50.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded up $0.68 during mid-day trading on Friday, hitting $23.93. 1,586,875 shares of the stock were exchanged, compared to its average volume of 1,188,894. The firm's 50-day simple moving average is $20.67 and its 200 day simple moving average is $18.00. The stock has a market capitalization of $2.84 billion, a price-to-earnings ratio of 43.06, a price-to-earnings-growth ratio of 3.47 and a beta of 0.75. Catalyst Pharmaceuticals has a fifty-two week low of $12.27 and a fifty-two week high of $24.27.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.13. The firm had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. On average, analysts predict that Catalyst Pharmaceuticals will post 1.82 EPS for the current fiscal year.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares of the company's stock, valued at $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Steve Miller sold 150,000 shares of the company's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares of the company's stock, valued at $13,738,773.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CPRX. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter valued at $426,000. Daiwa Securities Group Inc. bought a new stake in Catalyst Pharmaceuticals in the 1st quarter worth approximately $341,000. Mutual of America Capital Management LLC increased its position in shares of Catalyst Pharmaceuticals by 9.7% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,241 shares of the biopharmaceutical company's stock valued at $307,000 after purchasing an additional 1,701 shares during the last quarter. Texas Permanent School Fund Corp boosted its stake in Catalyst Pharmaceuticals by 12.9% during the first quarter. Texas Permanent School Fund Corp now owns 97,747 shares of the biopharmaceutical company's stock worth $1,558,000 after buying an additional 11,176 shares during the period. Finally, Oppenheimer & Co. Inc. bought a new position in Catalyst Pharmaceuticals during the 1st quarter valued at about $805,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.